Biogen said total revenue for Q3 2024 was $2,466 million, down 3% from $2,530 million a year earlier. The company reported GAAP diluted EPS of $2.66 and Non-GAAP diluted EPS of $4.08.

1. 01

   Biogen said total revenue for Q3 2024 was $2,466 million, down 3% from $2,530 million a year earlier. The company reported GAAP diluted EPS of $2.66 and Non-GAAP diluted EPS of $4.08.

2. 02

   Biogen reported that multiple sclerosis (MS) product revenue for Q3 fell 9% year over year to $1,054 million, while rare disease revenue rose 10% to $495 million.

3. 03

   Biogen said net cash flow from operations for Q3 2024 was about $936 million, capital expenditures were about $35 million, and free cash flow was about $901 million. Net debt as of September 30, 2024 was about $4.6 billion.

4. 04

   Biogen raised its full-year 2024 Non-GAAP diluted EPS outlook to $16.10 to $16.60 from the prior $15.75 to $16.25. The company said it maintained its expectation for a low-single digit percentage decline in full-year total revenue.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.